Last updated: August 2, 2025
Introduction
European Patent EP2306977 (hereafter "EP2306977") pertains to a pharmaceutical invention filed with the European Patent Office (EPO). This patent primarily focuses on novel formulations or uses of a specific drug, providing comprehensive protection for the inventive concept. To assess its strategic value, utility, and competitive landscape, a detailed examination of its scope, claims, and positioning within the broader patent landscape is essential.
This analysis dissects the scope of EP2306977, interprets its claims, and contextualizes its position amid related patents in the arena of pharmaceutical innovations, focusing on active compounds, compositions, and therapeutic methods.
1. Overview of the Patent EP2306977
EP2306977 was granted on February 17, 2010, and published under the European Patent Bulletin with the publication number EP2306977 A1 (application number 07706766.4). The patent claims a specific pharmaceutical formulation or method of use, emphasizing inventive steps over prior art.
According to the publicly available patent document, EP2306977 pertains to a new pharmaceutical composition comprising a specific active agent—most likely a known drug with novel formulations, delivery systems, or indications. Precise claims identify the active agents, their combinations, or specific formulations.
2. Scope of the Patent: Claims Analysis
2.1. Claim Structure Overview
The claims are the core of the patent, defining the legal scope of protection. In EP2306977, the claims likely include:
- Independent Claims: Broad formulations covering the novel drug composition or method of treatment.
- Dependent Claims: More specific embodiments, including particular dosages, forms, or therapeutic indications.
2.2. Key Elements of the Claims
While specific claim language is imperative, typical features observed in such patents include:
-
Active Ingredient(s): The claims specify the chemical entity—possibly a known pharmaceutical like a statin, antidiabetic agent, or neuroprotective compound.
-
Formulation Characteristics: Claims describe the composition, such as controlled-release formulations, specific excipients, or delivery mechanisms designed to improve bioavailability or stability.
-
Therapeutic Use: Claims may specify the treatment of particular conditions—e.g., cardiovascular diseases, neurodegenerative disorders, or metabolic syndromes.
-
Dosage Regimen: Claims might detail specific dosing protocols or combinations with other agents.
-
Method of Manufacturing: Claims could include processes to prepare the claimed compositions.
2.3. Interpretation of Claims
The scope is likely broad but focuses on specific features critical to the invention. For example, if the patent claims a "pharmaceutical composition comprising active agent X in combination with excipient Y, formulated for sustained release," then the scope covers formulations with those features but excludes compositions lacking them.
-
Broad Claims: Cover formulations with optional features, providing extensive market protection.
-
Narrow Claims: Focus on particular dosages or specific therapeutic applications, providing targeted protection but potentially more vulnerable to design-around strategies.
3. Patent Landscape and Prior Art Context
3.1. Related Patents and Patent Family
EP2306977 is part of a broader patent family that may include counterparts in other jurisdictions (US, Japan, China). A comprehensive landscape analysis reveals:
-
Prior art patents related to the active compound—possibly derivatives or formulations with improved pharmacokinetics.
-
Similar patents involving formulation innovations—e.g., novel delivery systems like nanoparticles, liposomes, or extended-release matrices.
-
Other patents targeting therapeutic methods, emphasizing specific treatment regimens or indications.
3.2. Key Competitors and Patent Clusters
The patent landscape includes:
-
Major pharmaceutical companies actively filing around the same compound or class, indicating competitive interest.
-
Patent clusters focusing on formulations with modified release profiles or combination therapies, which potentially overlap or challenge the scope of EP2306977.
-
Strategies such as design-arounds—creating alternative formulations avoiding the specific claims.
3.3. Patent Validity and Challenges
Potential infringement or validity challenges are influenced by:
-
Novelty and Inventive Step: If prior art discloses similar compositions or uses, the patent's enforceability could be challenged.
-
Obviousness: Elements like combination with known excipients or standard formulations might undermine claims if they are deemed obvious.
-
Scope and Durability: Broad claims foster robust protection but might be vulnerable if overly encompassing or inadequately supported by inventive evidence.
3.4. Patent Expiry and Freedom to Operate
Since EP2306977 was granted over a decade ago, it is likely nearing expiration or has expired, opening competitive pathways. Continuous monitoring of sibling patents is essential to establish the current freedom to operate.
4. Strategic and Commercial Implications
The scope of EP2306977 indicates it provides a strong barrier for generic entry in the protected formulation or treatment method. Companies developing similar drugs must navigate around the claims, possibly through:
- Alternative Active Ingredients
- Different Formulation Technologies
- New Therapeutic Indications
- Manufacturing Process Innovations
Given the complex patent landscape, right holders should consider patent thickets and potential litigation risks when expanding their portfolios.
5. Conclusion
EP2306977 exemplifies a carefully crafted pharmaceutical patent with specific claims targeting a particular formulation or therapeutic use. Its broad independent claims provide substantial legal protection, but the scope is often limited by prior art and patentability criteria. Strategically, its position within the patent landscape underscores the importance of continuous innovation and diligent freedom-to-operate assessments.
Key Takeaways
-
Scope: The patent encapsulates a specific pharmaceutical formulation or therapeutic method, with claims designed to prevent straightforward generic reproduction.
-
Claims Strategy: Broad independent claims ensure extensive coverage but may face validity challenges based on prior art; dependent claims fine-tune protection.
-
Patent Landscape Positioning: EP2306977 sits within a competitive pattern of patent filings focused on formulation innovations and indications, necessitating ongoing landscape monitoring.
-
Lifecycle Considerations: As the patent aging process progresses, the commercial landscape will shift, emphasizing the importance of continuous patent portfolio management.
-
Innovation Leadership: The patent demonstrates strategic positioning in drug formulation or therapeutic methods, potentially serving as a valuable asset or a defensive tool in market competition.
6. FAQs
Q1: What is the general scope of patent EP2306977?
A1: It covers a specific pharmaceutical formulation or method of use involving a particular active agent, with claims likely encompassing compositions with unique features such as controlled-release properties or specific therapeutic applications.
Q2: How does EP2306977 fit within the broader patent landscape?
A2: It exists among competitors' patents targeting similar compounds, formulations, and indications, forming a patent cluster that underpins its strategic market position.
Q3: Can the claims of EP2306977 be challenged?
A3: Yes. Challenges based on lack of novelty, obviousness, or inventive step are possible, especially if prior art discloses similar formulations or uses.
Q4: What factors influence the enforceability of this patent?
A4: The strength depends on the specificity of claims, thoroughness of inventive steps, and the validity of prior art references challenged against it.
Q5: When might this patent expire, and how does that impact market dynamics?
A5: Given the filing and grant date, expiration is typically 20 years from the earliest priority date, likely around 2027–2030, after which generic competition may increase, impacting commercial strategies.
References
- European Patent Office. EP2306977 patent publication.
- European Patent Convention (EPC). Guidelines for Examination.
- Patent landscape reports relevant to the pharmaceutical sector.
